AU2017316255C1 - Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof - Google Patents

Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof Download PDF

Info

Publication number
AU2017316255C1
AU2017316255C1 AU2017316255A AU2017316255A AU2017316255C1 AU 2017316255 C1 AU2017316255 C1 AU 2017316255C1 AU 2017316255 A AU2017316255 A AU 2017316255A AU 2017316255 A AU2017316255 A AU 2017316255A AU 2017316255 C1 AU2017316255 C1 AU 2017316255C1
Authority
AU
Australia
Prior art keywords
antigen
monoclonal antibody
antibody
binding fragment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017316255A
Other languages
English (en)
Other versions
AU2017316255A1 (en
AU2017316255B2 (en
Inventor
Baiyong Li
Zhongmin Maxwell WANG
Yu Xia
Peng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTTQ Akeso Shanghai Biomed Tech Co Ltd
Original Assignee
CTTQ Akeso Shanghai Biomed Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTTQ Akeso Shanghai Biomed Tech Co Ltd filed Critical CTTQ Akeso Shanghai Biomed Tech Co Ltd
Publication of AU2017316255A1 publication Critical patent/AU2017316255A1/en
Assigned to CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. reassignment CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Request for Assignment Assignors: AKESO BIOPHARMA, INC.
Publication of AU2017316255B2 publication Critical patent/AU2017316255B2/en
Priority to AU2024202527A priority Critical patent/AU2024202527B2/en
Application granted granted Critical
Publication of AU2017316255C1 publication Critical patent/AU2017316255C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
AU2017316255A 2016-08-23 2017-08-22 Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof Active AU2017316255C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202527A AU2024202527B2 (en) 2016-08-23 2024-04-17 Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610705763.5A CN106977602B (zh) 2016-08-23 2016-08-23 一种抗pd1单克隆抗体、其药物组合物及其用途
CN201610705763.5 2016-08-23
PCT/CN2017/098465 WO2018036472A1 (zh) 2016-08-23 2017-08-22 一种抗pd1单克隆抗体、其药物组合物及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202527A Division AU2024202527B2 (en) 2016-08-23 2024-04-17 Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Publications (3)

Publication Number Publication Date
AU2017316255A1 AU2017316255A1 (en) 2019-04-11
AU2017316255B2 AU2017316255B2 (en) 2024-02-01
AU2017316255C1 true AU2017316255C1 (en) 2024-08-22

Family

ID=59340342

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017316255A Active AU2017316255C1 (en) 2016-08-23 2017-08-22 Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof
AU2024202527A Active AU2024202527B2 (en) 2016-08-23 2024-04-17 Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202527A Active AU2024202527B2 (en) 2016-08-23 2024-04-17 Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Country Status (22)

Country Link
US (2) US12076398B2 (enExample)
EP (2) EP3505535B1 (enExample)
JP (1) JP7082620B2 (enExample)
KR (1) KR102469286B1 (enExample)
CN (1) CN106977602B (enExample)
AU (2) AU2017316255C1 (enExample)
BR (1) BR112019003775A2 (enExample)
EA (1) EA201990570A1 (enExample)
ES (1) ES3001154T3 (enExample)
FI (1) FI3505535T3 (enExample)
HU (1) HUE069593T2 (enExample)
IL (1) IL264956B2 (enExample)
LT (1) LT3505535T (enExample)
MX (1) MX2019002268A (enExample)
NZ (1) NZ751902A (enExample)
PL (1) PL3505535T3 (enExample)
PT (1) PT3505535T (enExample)
RS (1) RS66372B1 (enExample)
SG (1) SG11201901584UA (enExample)
SI (1) SI3505535T1 (enExample)
WO (1) WO2018036472A1 (enExample)
ZA (1) ZA201901781B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
SMT202200118T1 (it) 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
CN109425736B (zh) * 2017-08-25 2021-04-09 北京百普赛斯生物科技股份有限公司 一种检测pd-1抗体血药浓度的方法及试剂盒
KR20200059243A (ko) * 2017-09-20 2020-05-28 리제너론 파마슈티칼스 인코포레이티드 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CN112584901A (zh) * 2018-04-04 2021-03-30 真和制药有限公司 用于阻断非糖基化的pd-1多肽之间的相互作用的方法和组合物
SG11202009986QA (en) 2018-05-07 2020-11-27 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
US12390458B2 (en) 2018-07-18 2025-08-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Therapeutic combination of quinoline derivative and antibody
CN109053889B (zh) * 2018-07-25 2019-06-21 博奥信生物技术（南京）有限公司 一种抗人pd1单克隆抗体及用途
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US20220175815A1 (en) 2019-04-03 2022-06-09 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
CN110373415B (zh) * 2019-06-12 2023-06-09 安徽省昂普拓迈生物科技有限责任公司 特异性结合pd-l1蛋白的核酸适配体及其用途
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
EP4008351A4 (en) 2019-08-02 2023-08-09 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and medical use thereof
US20220275089A1 (en) * 2019-08-02 2022-09-01 Akeso Pharmaceuticals, Inc. Anti-ctla4-anti-pd-1 bispecific antibody and uses thereof
JP7771749B2 (ja) 2019-08-08 2025-11-18 小野薬品工業株式会社 二重特異性タンパク質
CN110903391B (zh) * 2019-10-25 2021-05-28 东大生物技术(苏州)有限公司 一组pd-l1单克隆抗体及其医药用途
CN112915202B (zh) * 2019-12-06 2025-08-01 正大天晴药业集团股份有限公司 喹啉衍生物与pd-1单抗的药物组合
WO2021121373A1 (zh) * 2019-12-20 2021-06-24 广东菲鹏制药股份有限公司 抗人程序死亡因子-1单克隆抗体
CN113117072A (zh) * 2020-01-14 2021-07-16 正大天晴药业集团股份有限公司 喹啉衍生物与pd-1单抗的药物组合
US20230045494A1 (en) 2020-02-28 2023-02-09 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
PH12022552785A1 (en) * 2020-04-22 2024-03-25 Akeso Biopharma Inc Anti-cd73-anti-pd-1 bispecific antibody and use thereof
AU2021263650A1 (en) 2020-04-29 2023-01-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bifunctional protein against PD-1 and TGF-beta
CN113754767A (zh) * 2020-06-03 2021-12-07 上海恒润达生生物科技股份有限公司 抗人pd-1抗体及其用途
WO2022068891A1 (zh) * 2020-09-30 2022-04-07 苏州沙砾生物科技有限公司 Pd-1抗体及其制备方法与应用
CN117580859A (zh) 2020-11-17 2024-02-20 思进股份有限公司 用图卡替尼和抗pd-1/抗pd-l1抗体的组合治疗癌症的方法
CN113336848B (zh) * 2021-02-03 2022-08-19 上海莱馥医疗科技有限公司 一种抗pd-1抗体及其用途
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
IL311738A (en) 2021-09-29 2024-05-01 Akeso Biopharma Inc ANTI-LAG3 antibody, drug composition and use
US20250002600A1 (en) 2021-10-06 2025-01-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
CN113912710B (zh) * 2021-11-17 2023-05-26 杭州旭科生物技术有限公司 抗新型冠状病毒n蛋白的单克隆抗体及其应用
CN114316053B (zh) * 2021-12-20 2023-09-29 南京诺唯赞检测技术有限公司 一种vce的单克隆抗体及其制备方法
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors
WO2023198060A1 (zh) * 2022-04-12 2023-10-19 正大天晴药业集团股份有限公司 蛋白酶体抑制剂与抗pd-1抗体的药物组合
AU2023269545A1 (en) 2022-05-12 2024-11-14 BioNTech SE Binding agents capable of binding to cd27 in combination therapy
WO2023217987A1 (en) * 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
US20250282873A1 (en) 2022-05-13 2025-09-11 Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
CN119789867A (zh) * 2022-09-06 2025-04-08 正大天晴药业集团股份有限公司 结合tim-3的抗体与结合pd-1的抗体的药物组合
CN120225558A (zh) * 2022-10-05 2025-06-27 朱拉隆功大学 针对人程序性细胞死亡蛋白1(pd-1)的单克隆抗体
CN117986356B (zh) * 2022-10-27 2025-07-22 纽迈生物科技(苏州)有限公司 一种制备抗体的方法
EP4626446A1 (en) 2022-12-01 2025-10-08 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2025056011A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物
WO2025056014A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
CN118652343B (zh) * 2024-07-08 2025-05-09 吉林省医菲尼迪生物医药有限公司 一种临床血液免疫细胞以及在治疗疾病中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175544A (zh) * 2015-10-20 2015-12-23 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CA2830806C (en) * 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
JP6072771B2 (ja) * 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
CN104936982B (zh) * 2012-08-03 2020-04-24 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SI3049441T1 (sl) 2013-09-27 2020-03-31 F. Hoffmann-La Roche Ag Formulacije protiteles proti PD-L1
ES2746805T3 (es) * 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN104974253A (zh) 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN104987421A (zh) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
CN105175545B (zh) * 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd-1双功能抗体及其应用
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
CN105754990A (zh) 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 一种pd-1/ctla-4双特异性抗体的制备方法及其应用
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175544A (zh) * 2015-10-20 2015-12-23 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用

Also Published As

Publication number Publication date
US12076398B2 (en) 2024-09-03
JP7082620B2 (ja) 2022-06-08
CN106977602A (zh) 2017-07-25
CA3034849A1 (en) 2018-03-01
US20250041409A1 (en) 2025-02-06
AU2017316255A1 (en) 2019-04-11
EP3505535A1 (en) 2019-07-03
EP4509186A3 (en) 2025-06-04
SG11201901584UA (en) 2019-03-28
IL264956B2 (en) 2023-04-01
AU2024202527A1 (en) 2024-05-16
SI3505535T1 (sl) 2025-04-30
ES3001154T3 (es) 2025-03-04
AU2017316255B2 (en) 2024-02-01
MX2019002268A (es) 2019-10-21
ZA201901781B (en) 2023-10-25
US20190321466A1 (en) 2019-10-24
IL264956A (en) 2022-12-01
EP3505535A4 (en) 2020-04-15
EP4509186A2 (en) 2025-02-19
LT3505535T (lt) 2025-01-27
JP2019534034A (ja) 2019-11-28
FI3505535T3 (fi) 2025-01-09
HUE069593T2 (hu) 2025-03-28
WO2018036472A1 (zh) 2018-03-01
AU2024202527B2 (en) 2026-01-15
RS66372B1 (sr) 2025-02-28
KR102469286B1 (ko) 2022-11-22
NZ751902A (en) 2022-05-27
EA201990570A1 (ru) 2019-08-30
PT3505535T (pt) 2025-01-13
BR112019003775A2 (pt) 2019-06-25
PL3505535T3 (pl) 2025-03-24
KR20190050994A (ko) 2019-05-14
CN106977602B (zh) 2018-09-25
EP3505535B1 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
AU2017316255C1 (en) Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof
US12479919B2 (en) Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
CN106632674A (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
JP2024514246A (ja) Ｃｌｄｎ１８．２抗原結合タンパク質およびその使用
EP3774898A1 (en) Anti-cd27 antibodies and use thereof
CA3034849C (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
HK40121274A (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
HK40010330B (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
HK40010330A (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
HK40103571A (en) Cldn18.2 antigen-binding protein and use thereof
HK40011027A (en) Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
EA042479B1 (ru) Моноклональное антитело против pd1, его фармацевтическая композиция и их применение
EA042365B1 (ru) Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CTTQ-AKESO (SHANGHAI) BIOMED. TECH. CO., LTD.

Free format text: FORMER APPLICANT(S): AKESO BIOPHARMA, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 APR 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 29 APR 2024

FGA Letters patent sealed or granted (standard patent)